Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 401 to 450 of 600 results for women's health

  1. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  2. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  3. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.

  4. Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)

    NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .

  5. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  6. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.

  7. Impact of neonatal infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family?

    infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family? Any...

  8. Fungitell for antifungal treatment stratification (MIB118)

    NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .

  9. Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.

  10. Improving baseline assessment for newly diagnosed hypertensive patients and optimising therapy

    hypertension in those aged over 35 years in the 2010 health survey for England was 31% in men and 28% in women. We carried...

  11. COVID-19 ready rehabilitation for heart failure: REACH-HF can deliver

    Exeter, Glasgow, Plymouth and York together with the Aneurin Bevan University Health Board, NHS Lothian, Ninewells Hospital & Medical...

  12. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available

  13. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

  14. eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)

    NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .

  15. Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia (MIB22)

    NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .

  16. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

  17. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    NICE has developed a medtech innovation briefing (MIB) on QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) .

  18. Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)

    NICE has developed a medtech innovation briefing (MIB) on Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease .

  19. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

  20. What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

    of particular interest: ethnicity children and young people pregnant women vaccination status people with comorbidities people who are...

  21. Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

  22. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

  23. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication....

  24. Needle-free arterial non-injectable connector (MIB85)

    NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .

  25. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  26. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.

  27. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

    Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in

  28. Liposuction for chronic lipoedema (IPG721)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

  29. Osteoarthritis in over 16s: diagnosis and management (NG226)

    This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.

  30. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  31. The Space GlucoseControl system for managing blood‑glucose in critically ill patients in intensive care (MIB17)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive

  32. Bair Hugger for measuring core temperature during perioperative care (MIB99)

    NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .

  33. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

  34. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  35. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

  36. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative

  37. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .

  38. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

  39. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

  40. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

  41. Biopatch for venous or arterial catheter sites (MIB117)

    NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .

  42. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  43. CytoSorb therapy for sepsis (MIB87)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .

  44. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

    NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

  45. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

  46. Immunosuppressive therapy for kidney transplant in adults (TA481)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  47. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

  48. Incorporating NICE guidance into the Sepsis Care Pathway at Tameside: improving patient care, safety and mortality in relation to sepsis

    surgery and full Consultant led obstetric and paediatric hospital services for women, children and babies. How did you implement the...